Objective Evaluation of cell-free DNA (cf-DNA) as a noninvasive tool to discriminate between malignant and benign ovarian growth.Patients and methods DNA was extracted from the plasma of 50 women with ovarian lesion. A total of 20 women with pathologically proven malignancy and 30 women with benign ovarian lesions were included. Quantification of cf-DNA was performed using real-time PCR. cf-DNA was correlated with the histopathology. ResultsThe preoperative plasma cf-DNA level was statistically significantly higher (P < 0.0001) in the malignant group (3.6 ± 1.7 ng/ll) compared with the benign group (0.71 ± 0.69 ng/ml) with 5.04-fold higher in the malignant group than in the benign counterpart. The mean level of cf-DNA in women with benign ovarian lesion (0.71 ± 0.69 ng/ml) did not reach statistically significant difference (P = 0.2) when compared with the mean level among women having endometriotic cysts (0.60 ± 0.44 ng/ml). In addition, there was no correlation between the CA-125 and cf-DNA levels (r = 0.127, P = 0.07), with sensitivity of 96% and specificity of 84%, with a cutoff limit of 1.4 ng/ml in diagnosing malignancy.Conclusion Detection of cf-DNA holds promise as a diagnostic test for women with ovarian cancer. We recommend its incorporation into the workup investigations for women attending with adnexal mass.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.